Life sciences firms secured $1.8 billion in venture capital investments during the third quarter with 170 deals, an 18% drop from the second quarter, according to a PricewaterhouseCoopers report. Tracy Lefteroff of PwC US pointed to regulatory challenges, difficulty with IPOs and equity market volatility as reasons.
Biotech firms raised $1.8 billion in Q3 venture funding
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||